VNVC and Sanofi advance vaccine manufacturing in Vietnam

Positive5 min readAI-generated summary

Report this article

Tell us what is wrong. We read every report.

Report this article
VNVC and Sanofi advance vaccine manufacturing in Vietnam
Health

VietNamNet News

Vietnam and France reinforced plans to localize vaccine manufacturing as VNVC and Sanofi advanced their cooperation at a July 9 high-level conference in Hanoi. The partnership builds on an October 2024 agreement and focuses on research collaboration, workforce development and technology transfer to support vaccine self-sufficiency. VNVC is constructing a VNVC Vaccine and Biological Manufacturing Plant in Tay Ninh with an initial VND2.5 trillion investment, about 26,000 square meters and a planned capacity of roughly 100 million doses annually; operations are targeted by the end of 2027 with first domestic batches expected in 2028.

Local vaccine production scheduled to begin supplying doses from 2028

Context

Vietnam and France held a joint high-level conference on July 9 to advance vaccine cooperation. The countries agreed steps to localize production and plan plant operations by 2027 and first batches in 2028.

The full analysis

19 dimensions on this story — world impact, market read, and what happens next.

  • Full ContextLocked
  • Affected SectorsLocked
  • Stock ImpactLocked
  • Economic IndicatorLocked
  • Investor RelevanceLocked
  • Professional RelevanceLocked
  • Watch PointsLocked
  • Probability of ChangeLocked
  • Debate PointsLocked
  • Follow-up QuestionsLocked
  • Pros & ConsLocked
Read free — no credit card